HLA-A*0201 & B2M & hTERT (ILAKFLHWL) Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| JWATM-203 | JWATM-203; JWATM203 | Phase 2 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details |
| SynOV1.1 | Phase 2 Clinical | Beijing Syngentech Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details | |
| ET140203 | Phase 2 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Hepatoblastoma; Carcinoma, Hepatocellular | Details | |
| Alpha fetoprotein targeted T-cell therapy (Adaptimmune) | AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T | Phase 1 Clinical | Adaptimmune Llc | Liver Neoplasms | Details |
| HRYZ-T102 | HRYZ-T102 | Phase 1 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| ET1402L1-CART | AFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202 | Phase 1 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| TAEST-1901 | TAEST-1901 | Phase 1 Clinical | Xiangxue Life Science Technology (Guangdong) Co Ltd | Liver Neoplasms; Neoplasms | Details |
| ET1402L1-ARTEMIS T cells | Phase 1 Clinical | Aeon Therapeutics (Beijing) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details | |
| CPU-118 | CPU-118 | Phase 1 Clinical | China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms | Details |